Antiglaucoma medications during pregnancy and the risk of low birth weight: A population-based study

J. D. Ho, C. C. Hu, H. C. Lin

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: To study the relationship between using antiglaucoma medications during pregnancy and the risk of having low-birth-weight (LBW) infants. Methods: The study group comprised 244 pregnant women who had been prescribed topical medication to control glaucoma during pregnancy. The comparison group comprised 1952 pregnant women matched for age, year of delivery, maternal hypertension and gestational diabetes. Multivariate logistic regressions were conducted to calculate the adjusted odds ratio of having LBW infants. Results: The majority of pregnant women (77.5%) were prescribed beta-blockers to control glaucoma. After adjusting for characteristics of the infant (gender, parity and gestational age), mother (age, the highest educational level, marital status, hypertension and gestational diabetes), father (the highest educational level), parental age difference and family monthly income, there was no significant difference in the risk of LBW infants between mothers prescribed beta-blockers and mothers in the comparison cohort (adjusted odds ratio (OR) 1.48, 95% CI 0.86 to 2.56). However, there was a significantly higher risk of LBW infants for mothers prescribed topical antiglaucoma medications other than beta-blockers (adjusted OR 2.15, 95% CI 1.05 to 5.00). Conclusions: Topical beta-blockers can be the first-line drugs when considering medical treatment of glaucoma in a pregnant woman.

Original languageEnglish
Pages (from-to)1283-1286
Number of pages4
JournalBritish Journal of Ophthalmology
Volume93
Issue number10
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Low Birth Weight Infant
Pregnant Women
Mothers
Glaucoma
Pregnancy
Gestational Diabetes
Odds Ratio
Population
Surrogate Mothers
Hypertension
Marital Status
Parity
Fathers
Gestational Age
Parents
Logistic Models
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Antiglaucoma medications during pregnancy and the risk of low birth weight : A population-based study. / Ho, J. D.; Hu, C. C.; Lin, H. C.

In: British Journal of Ophthalmology, Vol. 93, No. 10, 10.2009, p. 1283-1286.

Research output: Contribution to journalArticle

@article{9383fb5da801487b933bba14584aade1,
title = "Antiglaucoma medications during pregnancy and the risk of low birth weight: A population-based study",
abstract = "Objective: To study the relationship between using antiglaucoma medications during pregnancy and the risk of having low-birth-weight (LBW) infants. Methods: The study group comprised 244 pregnant women who had been prescribed topical medication to control glaucoma during pregnancy. The comparison group comprised 1952 pregnant women matched for age, year of delivery, maternal hypertension and gestational diabetes. Multivariate logistic regressions were conducted to calculate the adjusted odds ratio of having LBW infants. Results: The majority of pregnant women (77.5{\%}) were prescribed beta-blockers to control glaucoma. After adjusting for characteristics of the infant (gender, parity and gestational age), mother (age, the highest educational level, marital status, hypertension and gestational diabetes), father (the highest educational level), parental age difference and family monthly income, there was no significant difference in the risk of LBW infants between mothers prescribed beta-blockers and mothers in the comparison cohort (adjusted odds ratio (OR) 1.48, 95{\%} CI 0.86 to 2.56). However, there was a significantly higher risk of LBW infants for mothers prescribed topical antiglaucoma medications other than beta-blockers (adjusted OR 2.15, 95{\%} CI 1.05 to 5.00). Conclusions: Topical beta-blockers can be the first-line drugs when considering medical treatment of glaucoma in a pregnant woman.",
author = "Ho, {J. D.} and Hu, {C. C.} and Lin, {H. C.}",
year = "2009",
month = "10",
doi = "10.1136/bjo.2008.157123",
language = "English",
volume = "93",
pages = "1283--1286",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "10",

}

TY - JOUR

T1 - Antiglaucoma medications during pregnancy and the risk of low birth weight

T2 - A population-based study

AU - Ho, J. D.

AU - Hu, C. C.

AU - Lin, H. C.

PY - 2009/10

Y1 - 2009/10

N2 - Objective: To study the relationship between using antiglaucoma medications during pregnancy and the risk of having low-birth-weight (LBW) infants. Methods: The study group comprised 244 pregnant women who had been prescribed topical medication to control glaucoma during pregnancy. The comparison group comprised 1952 pregnant women matched for age, year of delivery, maternal hypertension and gestational diabetes. Multivariate logistic regressions were conducted to calculate the adjusted odds ratio of having LBW infants. Results: The majority of pregnant women (77.5%) were prescribed beta-blockers to control glaucoma. After adjusting for characteristics of the infant (gender, parity and gestational age), mother (age, the highest educational level, marital status, hypertension and gestational diabetes), father (the highest educational level), parental age difference and family monthly income, there was no significant difference in the risk of LBW infants between mothers prescribed beta-blockers and mothers in the comparison cohort (adjusted odds ratio (OR) 1.48, 95% CI 0.86 to 2.56). However, there was a significantly higher risk of LBW infants for mothers prescribed topical antiglaucoma medications other than beta-blockers (adjusted OR 2.15, 95% CI 1.05 to 5.00). Conclusions: Topical beta-blockers can be the first-line drugs when considering medical treatment of glaucoma in a pregnant woman.

AB - Objective: To study the relationship between using antiglaucoma medications during pregnancy and the risk of having low-birth-weight (LBW) infants. Methods: The study group comprised 244 pregnant women who had been prescribed topical medication to control glaucoma during pregnancy. The comparison group comprised 1952 pregnant women matched for age, year of delivery, maternal hypertension and gestational diabetes. Multivariate logistic regressions were conducted to calculate the adjusted odds ratio of having LBW infants. Results: The majority of pregnant women (77.5%) were prescribed beta-blockers to control glaucoma. After adjusting for characteristics of the infant (gender, parity and gestational age), mother (age, the highest educational level, marital status, hypertension and gestational diabetes), father (the highest educational level), parental age difference and family monthly income, there was no significant difference in the risk of LBW infants between mothers prescribed beta-blockers and mothers in the comparison cohort (adjusted odds ratio (OR) 1.48, 95% CI 0.86 to 2.56). However, there was a significantly higher risk of LBW infants for mothers prescribed topical antiglaucoma medications other than beta-blockers (adjusted OR 2.15, 95% CI 1.05 to 5.00). Conclusions: Topical beta-blockers can be the first-line drugs when considering medical treatment of glaucoma in a pregnant woman.

UR - http://www.scopus.com/inward/record.url?scp=70349973081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349973081&partnerID=8YFLogxK

U2 - 10.1136/bjo.2008.157123

DO - 10.1136/bjo.2008.157123

M3 - Article

C2 - 19520696

AN - SCOPUS:70349973081

VL - 93

SP - 1283

EP - 1286

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 10

ER -